Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286294249> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W4286294249 endingPage "TPS11591" @default.
- W4286294249 startingPage "TPS11591" @default.
- W4286294249 abstract "TPS11591 Background: Patients with high-risk rhabdomyosarcoma (HR-RMS) continue to have poor outcomes with 3-year event free survival (EFS) rates of 30% or less despite chemotherapy dose intensification on recent cooperative group RMS trials. Vinorelbine (VINO) has demonstrated clinical activity in RMS patients with relapsed/refractory disease and shown to provide a survival benefit when given with oral cyclophosphamide as maintenance chemotherapy for a select group of patients that achieved first complete remission. Methods: ARST2031 is a randomized Phase 3 trial with the primary aim to compare event-free survival (EFS) of patients with HR-RMS treated with vincristine, dactinomycin and cyclophosphamide (VAC) followed by maintenance with vinorelbine and oral cyclophosphamide (VINO-CPO) or vinorelbine, dactinomycin and cyclophosphamide (VINO-AC) followed by maintenance with VINO-CPO. Patients are stratified by histology and randomly assigned to VAC followed by VINO-CPO maintenance or VINO-AC followed by VINO-CPO maintenance. To be eligible, patients must be ≤ 50 years of age at the time of enrollment with newly diagnosed RMS except adult-type pleomorphic, based upon institutional histopathologic classification. All patients must have Stage 4 disease and patients diagnosed with embryonal RMS (ERMS) must be ≥ 10 years of age. Patients with malignant cytology in cerebrospinal fluid, intra-parenchymal brain metastases, or diffuse leptomeningeal disease are excluded. The study was activated on September 13, 2021 and is anticipated to enroll approximately 4 patients per month. The planned sample size is 100 patients, with approximately 50 patients randomized to each arm. Safety and feasibility of VINO-AC will be assessed in the first 8 patients prior to randomization. The study will have power of 0.8 to detect a hazard ratio of 0.61 (74 events in total) when the one-sided Type I error rate is 0.10, with 30 months of accrual and 2 years of follow-up. The hazard ratio of 0.61 was determined by assuming piecewise exponential distributions and specifying the 2-year EFS of 46% vs. 28% and long-term EFS of 32% vs. 16%, based on prior outcome data. Biospecimens will be collected and banked for future use. Clinical trial information: NCT04994132." @default.
- W4286294249 created "2022-07-21" @default.
- W4286294249 creator A5002562302 @default.
- W4286294249 creator A5003760804 @default.
- W4286294249 creator A5009811689 @default.
- W4286294249 creator A5009997118 @default.
- W4286294249 creator A5010317769 @default.
- W4286294249 creator A5013683766 @default.
- W4286294249 creator A5014963717 @default.
- W4286294249 creator A5016324584 @default.
- W4286294249 creator A5035741796 @default.
- W4286294249 creator A5040103581 @default.
- W4286294249 creator A5043898160 @default.
- W4286294249 creator A5045312202 @default.
- W4286294249 creator A5045647252 @default.
- W4286294249 creator A5058747709 @default.
- W4286294249 creator A5062262297 @default.
- W4286294249 creator A5068787428 @default.
- W4286294249 creator A5071801742 @default.
- W4286294249 creator A5072042288 @default.
- W4286294249 creator A5078531443 @default.
- W4286294249 date "2022-06-01" @default.
- W4286294249 modified "2023-10-17" @default.
- W4286294249 title "ARST2031: A study to compare early use of vinorelbine and maintenance therapy for patients with high risk rhabdomyosarcoma." @default.
- W4286294249 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.tps11591" @default.
- W4286294249 hasPublicationYear "2022" @default.
- W4286294249 type Work @default.
- W4286294249 citedByCount "0" @default.
- W4286294249 crossrefType "journal-article" @default.
- W4286294249 hasAuthorship W4286294249A5002562302 @default.
- W4286294249 hasAuthorship W4286294249A5003760804 @default.
- W4286294249 hasAuthorship W4286294249A5009811689 @default.
- W4286294249 hasAuthorship W4286294249A5009997118 @default.
- W4286294249 hasAuthorship W4286294249A5010317769 @default.
- W4286294249 hasAuthorship W4286294249A5013683766 @default.
- W4286294249 hasAuthorship W4286294249A5014963717 @default.
- W4286294249 hasAuthorship W4286294249A5016324584 @default.
- W4286294249 hasAuthorship W4286294249A5035741796 @default.
- W4286294249 hasAuthorship W4286294249A5040103581 @default.
- W4286294249 hasAuthorship W4286294249A5043898160 @default.
- W4286294249 hasAuthorship W4286294249A5045312202 @default.
- W4286294249 hasAuthorship W4286294249A5045647252 @default.
- W4286294249 hasAuthorship W4286294249A5058747709 @default.
- W4286294249 hasAuthorship W4286294249A5062262297 @default.
- W4286294249 hasAuthorship W4286294249A5068787428 @default.
- W4286294249 hasAuthorship W4286294249A5071801742 @default.
- W4286294249 hasAuthorship W4286294249A5072042288 @default.
- W4286294249 hasAuthorship W4286294249A5078531443 @default.
- W4286294249 hasConcept C126322002 @default.
- W4286294249 hasConcept C141071460 @default.
- W4286294249 hasConcept C142724271 @default.
- W4286294249 hasConcept C168563851 @default.
- W4286294249 hasConcept C2776694085 @default.
- W4286294249 hasConcept C2776755627 @default.
- W4286294249 hasConcept C2778239845 @default.
- W4286294249 hasConcept C2778256501 @default.
- W4286294249 hasConcept C2778283404 @default.
- W4286294249 hasConcept C2779429289 @default.
- W4286294249 hasConcept C2780350996 @default.
- W4286294249 hasConcept C2780844630 @default.
- W4286294249 hasConcept C71924100 @default.
- W4286294249 hasConceptScore W4286294249C126322002 @default.
- W4286294249 hasConceptScore W4286294249C141071460 @default.
- W4286294249 hasConceptScore W4286294249C142724271 @default.
- W4286294249 hasConceptScore W4286294249C168563851 @default.
- W4286294249 hasConceptScore W4286294249C2776694085 @default.
- W4286294249 hasConceptScore W4286294249C2776755627 @default.
- W4286294249 hasConceptScore W4286294249C2778239845 @default.
- W4286294249 hasConceptScore W4286294249C2778256501 @default.
- W4286294249 hasConceptScore W4286294249C2778283404 @default.
- W4286294249 hasConceptScore W4286294249C2779429289 @default.
- W4286294249 hasConceptScore W4286294249C2780350996 @default.
- W4286294249 hasConceptScore W4286294249C2780844630 @default.
- W4286294249 hasConceptScore W4286294249C71924100 @default.
- W4286294249 hasFunder F4320332161 @default.
- W4286294249 hasIssue "16_suppl" @default.
- W4286294249 hasLocation W42862942491 @default.
- W4286294249 hasOpenAccess W4286294249 @default.
- W4286294249 hasPrimaryLocation W42862942491 @default.
- W4286294249 hasRelatedWork W1978070076 @default.
- W4286294249 hasRelatedWork W2036802760 @default.
- W4286294249 hasRelatedWork W2083438316 @default.
- W4286294249 hasRelatedWork W2111618869 @default.
- W4286294249 hasRelatedWork W2145349532 @default.
- W4286294249 hasRelatedWork W2330662417 @default.
- W4286294249 hasRelatedWork W2342164759 @default.
- W4286294249 hasRelatedWork W2418155614 @default.
- W4286294249 hasRelatedWork W4220653294 @default.
- W4286294249 hasRelatedWork W4318982698 @default.
- W4286294249 hasVolume "40" @default.
- W4286294249 isParatext "false" @default.
- W4286294249 isRetracted "false" @default.
- W4286294249 workType "article" @default.